Comrade B
EudraCT- Nummer: 2011-001019-30
A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant in patients with visual impairment due to macular edema following branch retinal vein occlusion (BRVO). Comparison of Lucentic (Ranibizumab) and Ozurdex (Dexamethasone) for the treatment of patients with visual impairment due to macular edema following branch retinal vein occlusion
Ansprechpartner: PD Dr. Felix Treumer
Comrade C
EudraCT- Nummer: 2011-001020-38
A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implant in patients with visual impairment due to macular edema following central retinal vein occlusion (CRVO). Comparison of Lucentic (Ranibizumab) and Ozurdex (Dexamethasone) for the treatment of patients with visual impairment due to macular edema following central retinal vein occlusion
Ansprechpartner: PD Dr. Felix Treumer
VIEW-2
EudraCT- Nummer: 2007-000583-25
A randomized, double masked, active controlled, phase 3 study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap-Eye in subjects with neovascular age-related macular degeneration (AMD)
Ansprechpartner: Dr. Heike Hasselbach
Relation
EudraCT- Nummer: 210-018852-29
Eine 12-monatige, zweiarmige, randomisierte, doppelblinde multizentrische Phase 3b Studie zur Beurteilung der Wirksamkeit und Sicherheit von Laserkoagulation als Zusatztherapie mit zu Ranibizumab (Intravitreale Injektionen) im Vergleich zur Laserkoagulation Monotherapie bei Patienten mit Visusverschlechterung hervorgerufen durch ein diab. Maculaödem, gefolgt von einer 12- moantigen Follow-up Periode.
Galileo
EudraCT- Nummer: 2009-010973-19
A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO)
Ansprechpartner: Dr. Heike Hasselbach
MD711- Pazopranib Eye Drops
EudraCT- Nummer: 2009-015106-19
A Phase 2b Dose-Evaluation Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration.
VIPER
EurdaCT-Nummer: nicht gefunden!!!
Titel
Ansprechparter: Prof. Dr. Jost Hillenkamp
Vivid
EudraCT- Nummer:2010-022364-12
Eine randomisierte, doppelt verblindete, aktiv kontrollierte, Phase-III-Studie zur Untersuchung der Wirksamkeit und Sicherheit wiederholter intravitrealer Dosierungen von VEGF Trap-Eye bei Patienten mit diabetischem Makular Ödem.
Ansprechpartner: Dr. Heike Hasselbach
Endure 2301
EudraCT- Nummer:2009-014835-19
A 24-week multicenter, randomized, double masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo for maintraining uveitis suppression when reducing systemic immunsuppression in patients with quiestcent, non-infectious intermediate, piosterior or panuveitis.
Ansprechpartner: Dr. Bernhard Nölle
Insure
EudraCT- Nummer:2009-014834-22
A 28-week multicenter, randomized, double masked, placebo controlled, dose-ranging phase III study of AIN457 versus placebo in inducing and maintraining uveitis suppression in adults with active, non-infectious, intermediate, piosterior or panuveitis requiring immunsuppression.
Ansprechpartner: Dr. Bernhard Nölle
Excite
EudraCT- Nummer:2005-00351733
A randomized, double-masked, active-controlled, multicenter study comparing the efficacy and safety of ranibizumab (0.3mg and 0.5mg) administered as two dosing regimes in patients with subfoveal choroidal neovaskularization secondary to age-related macular degeneration.
Ansprechpartner: Prof. Dr. Johann Roider
Secure
EudraCT- Nummer:2007-000743-95
A phase IV, long-term, open label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovaskularization (CNV) secondary to age-related macular degeneration (AMD).
Ansprechpartner: Prof. Dr. Johann Roider
Restore-Studie
EudraCT- Nummer:2007-004877-24
A randomized, double-masked, multicenter, lasercontrolled Phase III study assessing the efficacy and safety of ranibizumab (intravitreal injections) as adjunctive and mono-therapy in patients with visual impairment due to diabetic macular edema.
Ansprechpartner: Prof. Dr. Johann Roider